STAT3 and non-small cell lung carcinoma: The present study defined a pivotal role of EVs derived from Erlotinib‐resistant CSCs in the Erlotinib resistance of NSCLC and that RCSC‐EVs delivered APE1 into NSCLC to induce NSCLC resistance to Erlotinib by activating the IL‐6/STAT3 signalling (Figure 7).